6PE	Modified Form 1449/PTO	Application Number 10/809,944		
		Filing Date	March 25, 2004	
	information disclosure	First Named Inventor	Luc J. Farmer	
6	OTATELEEN ANDLICANT	Group Art Unit	1614 1624	
, (STATEMENT BY APPLICANT	Examiner Name	Not Yet Assigned	
جري ج	[<u>*</u>	Attorney Docket Number	VPV02-133 US	
AMEN				

	U.S. PATENT DOCUMENTS						
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials			n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
DR	ВІ	wo	03/011838 A1	Merck & Co., Inc.	13 February 2003		
DR	B2	wo	01/72745 A1	Cyclacel Limited	4 October 2001		
	.	ļ					ļ
		-	<u> </u>				<u> </u>
	 	-		- 			<u> </u>

	OTHER NON PATENT LITERATURE DOCUMENTS						
Exam Initials Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.							
DR	CI	Strawn et al., "Tyrosine Kinases in Disease: Overview of Kinase Inhibitors as Therapeutic Agents and Current Drugs in Clinical Trials", Expert Opinion on Investigational Drugs, 7(4): 553-573, (1998).					

* a copy of this reference is not provided as it v	was previously cited by or submitted to the office in a prior application,
	, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,
continuation-in-part, and divisional application	

Examiner Signature	/Deepak Rao/	Date Considered	08/03/2006
_		į	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.